<DOC>
	<DOCNO>NCT01376193</DOCNO>
	<brief_summary>The study design investigate information safety efficacy naratriptan tablet Japanese subject migraine headache Japanese post-marketing surveillance period .</brief_summary>
	<brief_title>Drug Use Investigation AMERGE ( Naratriptan Hydrochloride ) Tablet</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naratriptan</mesh_term>
	<criteria>Subjects migraine headache Must use naratriptan tablet first time Subjects hypersensitivity naratriptan Subjects history , symptom , sign myocardial infarction , ischemic cardiac disease , variant angina Subjects history peripheral vascular disorder Subjects history cerebrovascular disorder transient ischemic attack Subjects uncontrolled highblood pressure Subjects severe hepatic function disorder renal function disorder Subjects take ergotamine , ergotamine derivative contain product , 5HT1B/1D agonist</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>